Introduction
The HMG-I(Y) family of mammalian high mobility group (HMG) nonhistone proteins consists of three related members: HMG-I, HMG-Y and HMGI-C (reviewed in Bustin and Reeves, 1996) . HMG-I and -Y are isoform proteins derived by alternative splicing of transcripts from a single gene located on chromosome 6 in humans and chromosome 17 in mice, whereas HMGI-C is coded for by a separate gene located on chromosome 12 in humans and chromosome 10 in mice. Due to dierential splicing of the transcript coding region, the HMG-I protein contains 11 amino acids not present in HMG-Y. The functional signi®cance of this internal peptide stretch in the HMG-I isoform protein, or its absence in the -Y isoform, is at present unknown. HMG-I(Y) proteins recognize DNA structure, rather than sequence, and preferentially bind to the narrow minor groove of A⋅T-rich regions of B-form DNA by means of novel DNAbinding motifs called`A⋅T-hooks'. In vivo the HMG-I(Y) proteins function as architectural transcription factors; that is, they do not independently regulate gene transcription, but modulate expression through the formation of stereospeci®c complexes on the promoter/ enhancer regions of genes via direct interactions with other transcription factors and through substrate interactions that bend, unwind or distort the structure of DNA. In vivo, such stereospeci®c complexes may either enhance gene transcription (e.g. that of murine tumor necrosis factor-beta (Fashena et al., 1992) , human interferon-beta (Thanos and Maniatis, 1992; Du et al., 1993) , human interleukin-2 receptor-alpha (John et al., 1995) , human interleukin-2 (Himes et al., 1996) , human E-selectin (Lewis et al., 1994; Whitley et al., 1994) , human granulocyte-macrophage colony stimulating factor (Himes et al., 1996) or suppress transcription (e.g. that of human interleukin-4 (Chuvpilo et al., 1993) , human GP91-PHOX (Skalnik and Neufeld, 1992) , murine epsilon-immunoglobulin (Kim et al., 1995) and human gamma-globin (Margis and Martin, 1995) .
An ever-increasing body of evidence supports a link between HMG-I(Y) proteins and cancer (Bustin and Reeves, 1996; Wunderlich and Bottger, 1997) . HMG-I(Y) expression is elevated in human prostate, thyroid, and colorectal carcinomas (Tamimi et al., 1993; Chiappetta et al., 1995; Fedele et al., 1996) . HMG-I(Y) expression is also elevated in human uterine leiomyomata and pulmonary chondroid hamartomas, benign neoplasms (Williams et al., 1997; Xiao et al., 1997) . HMG-I(Y) levels are high in neoplastic compared to normal cell lines (Goodwin et al., 1985; Giancotti et al., 1985 Giancotti et al., , 1987 . Increasing levels of HMG-I(Y) are found with progression in a series of cell lines isolated from the Dunning rat model system of prostate cancer (Bussemakers et al., 1991) , as well as from a mouse mammary epithelial cell system (Ram et al., 1993) , where increasing levels of both HMG-I(Y) mRNAs and proteins correlated with increasing metastatic potential of the tumors.
To date, only one study has suggested a causal role for HMG-I(Y) protein in carcinogenesis. Berlingieri et al. (1995) demonstrated that transfection of rat thyroid cells with HMGI-C antisense expression constructs markedly lowered the endogenous levels of HMG-I(Y) proteins in these cells and blocked their susceptibility to transformation by either the v-mos or v-ras-Ki oncogenes. Interestingly, in these HMGI-C antisense experiments, the endogenous level of HMGI-C protein was only reduced in the cells, whereas the endogenous levels of both the HMG-I and HMG-Y proteins were completely eliminated. Together these results implicate the HMG-I(Y) proteins as key players in the transformation of these rat thyroid cells. In order to further address the role of HMG-I(Y) in multistage carcinogenesis, we have undertaken studies in the JB6 mouse epidermal cell model of mouse skin tumor promotion. This model has been employed to elucidate the role of AP-1 in tumor promoter-induced neoplastic transformation (Bernstein and Colburn, 1989; Dong et al., 1994) and to identify genes potentially involved in neoplastic progression (Cmarik et al., 1994; Sun et al., 1994) .
The JB6 model consists of multiple cell lines of each of three phenotypes: (1) preneoplastic, tumor promotion resistant (P7), (2) preneoplastic, tumor promotion sensitive (P+), and (3) neoplastic, transformed (Tx) cells (Colburn et al., 1978 (Colburn et al., , 1979 (Colburn et al., , 1980 (Colburn et al., , 1981 . JB6 P7 and P+ cell lines were derived from the same population of primary epidermal cells isolated from Balb/C mice. The P7 cells, when exposed to tumor promoters such as 12-O-tetradecanoyl phorbol acetate (TPA) or epidermal growth factor, retain their anchorage-dependent, non-tumorigenic phenotype. P+ cells, however, when exposed to tumor promoters, form anchorage-independent colonies in soft agar that are tumorigenic. Tx JB6 cell lines are anchorageindependent and tumorigenic and were established from tumor promoter-treated P+ cells. P7 and P+ cells do not dier in all their responses to tumor promoters; they exhibit similar mitogenic responses to TPA (Colburn et al., 1981) and show approximately 97% similarity of tumor promoter-induced gene expression by dierential display of mRNA (Cmarik, unpublished data) , and thus are uniquely appropriate for the identi®cation of transformation-relevant events.
We have compared the expression of both HMG-I(Y) transcript and protein levels in JB6 cells to determine whether there is a dierence in basal levels of expression between the phenotypes that might contribute to the propensity of P+ cells to become transformed, and to determine whether there are tumor promoter-induced changes in HMG-I(Y) expression that might play a role in neoplastic progression. From previous studies, we know that small, nuclear phosphoproteins are preferentially induced by tumor promoter in P+ cells, but their identities are unknown (Hirano et al., 1992) . In the present study, we found that there are both basal and tumor promoter-induced dierences in HMG-I(Y) expression in P7 and P+ cells that are candidates for causing transformation. In addition, our studies revealed the ®rst suggestion of a dierential function for the HMG-I and -Y isoform proteins with the novel ®nding that in contrast to the mRNA, the HMG-Y protein is markedly induced by tumor promoter in P+ but not in P7 cells. ) is also observed. These variations might be signi®cant as independent clones also exhibit some variation in phenotypic characteristics; however, because there is variation even amongst the lines of the Tx phenotype, the data suggest that a critical dierence in threshold level may occur between the amounts found in P7 cells and those found in P+ or Tx cells.
Results

Dierential
Dierential tumor promoter induction of HMG-I(Y) mRNA levels in transformation-sensitive and resistant variants
Previous work has demonstrated that HMG-I(Y) mRNA expression can be induced in a variety of cell types by phorbol esters such as TPA (Friedmann et al., 1993; Ogram and Reeves, 1995) . We therefore compared the levels of HMG-I(Y) mRNA in response to the tumor promoter TPA in P+ Cl 22 cells and P7 Cl 30-2a cells. Cells were exposed for 0 ± 24 h to 10 ng/ ml (16 nM) TPA, a concentration that yields *10 ± 20% anchorage-independent transformed colonies after 2 weeks exposure of P+ cells in agar. Higher HMG-I(Y) mRNA levels were induced in P+ than in P7 cells and were maintained in P+ cells at 24 h, whereas P7 cell levels had signi®cantly declined by 24 h (Figure 2 analysis. The results indicate that four major start sites, and what appear to be several minor ones, are utilized in the mouse gene ( Figure 3 ). Signi®cantly, one of these transcription start sites (at nucleotide *7330 from the translation start site) is upstream of the longest murine HMG-I(Y) cDNA clone previously isolated (Johnson et al., 1988) . There is no striking dierence between P+ and P7 cells in the frequency with which these sites are used. The start site at nucleotide 796 appears to be most frequently utilized in both P+ and P7 Analysis of HMG-I and -Y transcripts in JB6 cells by reverse transcriptase-polymerase chain reaction (RT ± PCR) reveals greater expression of Y Relative levels of HMG-I and -Y transcripts were measured by quantitative RT ± PCR utilizing primers that spanned the 33-nucleotide region present in I but spliced out in Y, yielding a longer PCR product for I than Y, and that also generated a HindIII-cleavable internal reference standard (IS) as described in Materials and methods (Figure 4a ). Transcript levels of Y were 1.2 ± 2.1-fold greater than levels of I in untreated P7, P+, and Tx JB6 cells (Figure 4b ). The combined levels of HMG-I plus Y transcripts determined by RT ± PCR in P7 and P+ cells re¯ect the same relative abundance of total HMG-I(Y) transcripts present in these cells as determined by Northern analysis (compare Figures 1 and 4b) . In response to TPA treatment, the induced level of Y was always greater than the level of I in both P+ Cl 41 cells and Immunoblotting with an antibody that recognizes both HMG-I and Y was carried out in order to compare both the steady-state constitutive and the TPAinducible levels of HMG-I and -Y proteins in P+ and P7 cells. The results of these experiments showed that, as in the case of mRNA levels, there were marked dierences between the P7 and P+ cells, both in their constitutive levels of HMG-I and -Y proteins and in the kinetics of induction of these proteins following TPA stimulation. The immunoblot in Figure 5 shows that basal levels of HMG-I and -Y proteins are much higher in P+ Cl 22 cells than in P7 Cl SC21 cells (HMG-I(Y) proteins are undetectable in untreated P7 cells in this experiment). Protein levels increased by *1.2-fold greater than the basal levels by 12 h in the P+ cells, and increased to comparable levels in the P7 cells. However, there is again a striking dierence in protein levels between P+ and P7 cells at 24 h: in P+ cells, the levels are greater than double the basal levels, whereas in P7 cells the levels have diminished dramatically to *1/3 the level in untreated P+ cells. In a separate experiment using dierent gel electrophoresis conditions (see Materials and methods), we were able to separate the I and Y isoform proteins (Figure 6 ), allowing comparison with the relative I and Y mRNA levels determined by RT ± PCR. As shown in Figure 6 , in the uninduced state, P+ Cl 41 cells constitutively expressed *2.6-fold higher levels of HMG-I protein than P7 Cl SC21 cells. Furthermore, by 12 h of TPA stimulation the induced level of HMG-I protein in P7 cells was HMG-Y induction with neoplastic transformation JL Cmarik et al *®vefold higher than the basal level in the uninduced cells, but by 24 h post-stimulation the protein level in the P7 cells had decreased to less than half this amount, as was also observed for the kinetics of induction of HMG-I mRNA levels in TPA-stimulated P7 cells (Figure 4c ). On the other hand, following TPA exposure of P+ cells, the kinetics of HMG-I protein induction are quite dierent from that in P7 cells. For example, although the HMG-I protein levels in P+ cells had also increased by 12 h of TPA exposure (to *threefold the level in untreated cells), in contrast to the P7 cells, the levels of protein continued to remain high in the TPA-treated cells, and by 24 h had actually increased (to *®vefold) rather than dropping as it did in P7 cells. Likewise for the HMG-Y protein, there is a marked dierence between P7 and P+ cells in both the constitutive and TPA-induced levels. Analysis of the immunoblot shown in Figure 6 indicates that P+ Cl 41 cells constitutively contain *1.5-fold more HMG-Y protein than P7 Cl SC21 cells. As was the case with the kinetics of induction of the HMG-I protein, when P+ cells were treated with TPA, the levels of HMG-Y continued to increase in the cells so that by 24 h they had accumulated greater than 3.3-fold the amount of protein found in uninduced P+ cells. In marked contrast to these results for the P+ cells, there was little stimulation of the HMG-Y protein in P7 cells at any time following treatment with TPA, despite the increase observed in HMG-Y mRNA in these cells following phorbol ester treatment (Figure 4c and d) . One possible artifactual explanation for the signi®cantly dierent results observed for TPA-induction of HMG-Y protein in the P7 and P+ cells is that the two dierent cell types could respond dierently to TPA stimulation by selective posttranslational modi®cation (e.g. by phosphorylation) of either the HMG-I or HMG-Y protein, and that these modi®ed forms of the protein(s) might co-migrate on the electrophoretic separation system employed and thus complicate interpretation of the immunoblots. To investigate this possibility we performed additional control experiments utilizing phosphatase treatment. The results indicated that HMG-I and -Y proteins are indeed phosphorylated in both P+ and P7 cells in response to TPA treatment. Nevertheless, under the conditions used for SDS-polyacrylamide gel electrophoresis (PAGE), none of the phosphorylated HMG-I and -Y species co-migrated with the dephosphorylated proteins (data not shown). Thus we conclude that, in contrast to the situation in P7 cells, P+ cells show marked induction of the HMG-Y isoform protein in response to TPA stimulation. We also conclude that the limited induction of the HMG-Y isoform protein relative to HMG-I in the P7 cells results from either dierential regulation of mRNA translation and/or dierences in protein stabilities in the P7 cells because both the constitutive and TPA-induced levels of HMG-Y mRNA are consistently higher than the HMG-I mRNA levels in these cells.
Discussion
These results demonstrate, for the ®rst time, a preferential induction of HMG-I(Y) in transformation-sensitive compared to transformation-resistant cells. Although variants of each progression phenotype showed some variation in levels of HMG-I(Y) mRNA, a major dierence in absolute HMG-I and HMG-Y transcript levels was consistently apparent between the P7 and P+ phenotypes. Likewise, although the fold induction of HMG-I(Y) mRNAs in response to TPA was higher in P7 cells than in P+ cells, the absolute HMG-I(Y) transcript levels were consistently higher and persisted longer in stimulated P+ cells than in stimulated P7 cells. Given the fact that HMG-I(Y) proteins are transcription factors, the higher basal levels of both HMG-I(Y) transcripts and proteins in unstimulated P+ and Tx cells compared to unstimulated P7 cells, as well as their greater TPA-induced accumulations in P+ compared to P7 cells, may suggest that these nonhistone proteins cooperate in the transcriptional regulation of a pool of genes necessary for susceptibility to, induction of, and/or maintenance of the transformed phenotype. Insucient HMG-I(Y) expression in P7 cells may not allow the expression of such genes. These transformation-mediating genes could be regulated by the transcription factors NF-kB or AP-1. Both NF-kB (Du et al., 1993; Reeves et al., unpublished data) HMG-I(Y). Furthermore, in the case of the NF-kB/ HMG-I(Y) interactions, it is known that the dimerization domain of NF-kB is required for interaction with HMG-I(Y) (Du et al., 1993) and that the region of HMG-I(Y) protein between the second and third A⋅T-hook DNA-binding domains is required for interaction with NF-kB (Reeves et al., unpublished data). Thus far, however, the interacting domains of the Jun and HMG-I(Y) proteins have not been identi®ed. Nevertheless, these protein-protein interactions may be of considerable biological importance because AP-1 transactivation has been shown to occur in response to tumor promoters consistently in P+ but not P7 cells (Bernstein and Colburn, 1989) . Studies with dominant-negative Jun and AP-1 transrepressing retinoids have demonstrated that activated AP-1 is necessary for the transformation of P+ cells by tumor promoter (Dong et al., 1994; Li et al., 1996) . NF-kB induction may also be necessary as these AP-1 inhibitors also block NF-kB transactivation (Li et al., 1997; Dong et al., 1997) . Alternatively, because HMG-I(Y) proteins are known to function as either transcriptional activators or repressors in vivo (reviewed in Bustin and Reeves, 1996) , it is also possible that HMG-I(Y) might suppress the expression of genes necessary to prevent transformation. Such genes could be expressed in P7 cells due to low levels of HMG-I(Y), but not in P+ cells in which HMG-I(Y) levels are higher, and might incude the candidate transformation inhibitors TIS1, TIS21 and Fra-related protein (Cmarik et al., 1994; Bernstein et al., 1992) . Through primer extension analysis, we found that four major transcription start sites are utilized within the mouse HMG-I(Y) gene in unstimulated JB6 cells. In the human gene, it was previously found that one of four start sites was selectively utilized in TPA induction of HMG-I(Y) mRNAs (Ogram and Reeves, 1995) . It was of interest to determine whether the same unique induction of a single start site occurred in JB6 cells in response to TPA. In contrast to the situation in human cells, we found that transcription from all four start sites increased in response to TPA in both P+ and P7 cells. Preferential utilization of a start site in P+ cells but not in P7 cells does not, therefore, contribute to the dierent levels of HMG-I(Y) mRNAs or proteins found in these cells.
The dierential constitutive expression of HMG-I(Y) mRNAs in P+ and Tx cells relative to P7 cells could arise from a number of causes: mutations in the promoter region of the HMG-I(Y) gene, altered chromatin con®guration or methylation of the gene, or dierential availability of transcription factors that activate HMG-I(Y) transcription. An attempt was made to utilize human HMG-I(Y) reporter constructs (Ogram and Reeves, 1995) to compare expression in the JB6 murine progression variants. These reporters did not, however, re¯ect the endogenous expression pattern, not a surprising outcome in light of the primer extension results that indicated very dierent regulation by TPA in human and mouse cells. Further analysis of the transcriptional promoter sequences that regulate HMG-I(Y) expression in JB6 cells awaits the successful completion of eorts to obtain a longer murine cDNA clone or a murine genomic clone.
The increase of HMG-Y protein in P+ but not in P7 cells is an unexpected and novel ®nding of potential signi®cance in transformation. The HMG-I(Y) proteins are thought to be involved in normal cellular growth regulation (Johnson et al., 1990; Lanahan et al., 1992; Zhou et al., 1995; Bustin and Reeves, 1996) and, perhaps signi®cantly, it has previously been reported that the HMG-Y protein isoform is preferentially induced, relative to HMG-I, in human peripheral blood lymphocytes stimulated with phytohemagglutinin (Giancotti et al., 1991) . HMG-I and -Y are splice variants that dier in 33 nucleotides; thus HMG-I includes an N-terminal stretch of 11 amino acids (VSPGTALVGSQ) not present in HMG-Y Friedmann et al., 1993) . Currently there is no known function of this 11 amino acid region which is conserved in the mouse and human HMG-I proteins, and there are no known dierential functions of I and Y proteins. The contrast in P7 cells between the RT ± PCR, which revealed higher levels of Y mRNA and a coordinate increase in I and Y mRNAs, and the immunoblotting, which revealed consistently higher levels of I than Y protein, suggest dierential post-transcriptional regulation of the splice variant favoring translation of I, and/or greater stability of I protein than Y in P7 cells. The 11 amino acids present in I (but not Y) might in¯uence protein stability or function, possibly through interaction with other proteins. The explanation of dierential protein stability appears unlikely because we have previously shown that both the HMG-I and HMG-Y proteins are extremely stable in cells (T1/24430 h; Holth et al., 1997) . Rather, preferential translation of the HMG-I transcript may occur. The functionally signi®cant limiting factor thus may be the HMG-Y protein levels. The HMG-Y isoform may exhibit protein-protein interactions not seen with I, for example with certain transcription factors, that in¯uence its ability to function in vivo as aǹ architectural transcription factor' (Bustin and Reeves, 1996) .
The functional signi®cance in neoplastic transformation of higher levels of expression of HMG-I(Y) proteins in P+ than P7 cells, in particular the Y protein, is the key question raised by the results presented here. It will be of interest to determine whether P7 cells that overexpress I and/or Y become susceptible to tumor promoter-induced transformation. It will also be of interest to determine whether tumor promoter-induced transformation is inhibited or occurs at a decreased frequency in P+ cells that express antisense or dominant-negative HMG-I(Y). Our initial attempts to isolate stable antisense transfectants have been unsuccessful because these clones grow very slowly, a fact that is suggestive of the role HMG-I(Y) may play in mediating JB6 cell growth and transformation.
Materials and methods
Cell culture and treatment of cells
The JB6 P7 (Cl 30-2a and Cl SC21), P+ (Cl 41 and Cl 22) and Tx (T 3 6274, RT101, JB8, and VB8) cell lines were derived from Balb/c mouse primary epidermal cell cultures (Colburn et al., 1978 (Colburn et al., , 1979 (Colburn et al., , 1980 (Colburn et al., , 1981 . The cells were routinely cultured in Eagle's minimal essential medium supplemented with 1% glutamine, 4% heat-inactivated fetal bovine serum, and antibiotics at 368C in a humidi®ed atmosphere containing 5% CO 2 . For TPA treatment, TPA (Chemicals for Cancer Research, Inc., Edina, MN) was dissolved in dimethyl sulfoxide and diluted to a concentration of 100 ng/ml in serum-free medium. One-tenth the ®nal volume was added to each¯ask of subcon¯uent cells to be treated and mixed with the medium already present to yield a ®nal TPA concentration of 10 ng/ml or 16 nM.
Preparation of total RNA
Total RNA was prepared from subcon¯uent cell cultures with RNA STAT-60 reagent (Tel-Test`B', Inc., Friendswood, TX) according to the manufacturer's protocol. The ®nal RNA pellet was resuspended in diethyl pyrocarbonate-treated distilled H 2 O, and the RNA concentration was determined spectrophotometrically.
Northern blot analysis
RNA samples (20 mg) were subjected to electrophoresis through 1.2% agarose-formaldehyde gels. RNA size standards (Gibco ± BRL, Gaithersburg, MD) were included to allow approximation of mRNA sizes. Integrity of the total RNA preparations was con®rmed by ethidium bromide staining. The RNA was then transferred to Zetabind cationic nylon membranes (CUNO, Inc., Meriden, CT) as described previously (Ben-Ari et al., 1992) . The full-length murine HMG-I(Y) cDNA clone (Johnson et al., 1988) was 32 P-radiolabeled by random oligonucleotide-primed synthesis (Ausubel et al., 1989) and used as a hybridization probe. Northern blots were prehybridized for 3 h at 428C in 40% formamide, 0.5 M sodium phosphate, pH 7.2, 1 mM EDTA, 5% SDS and 1% bovine serum albumin; denatured labeled probe DNA (2610 6 c.p.m./ml) was then added and the hybridization continued for at least 20 h. Final washes were in 16SSPE (36 mM sodium chloride, 2 mM sodium phosphate, 0.2 mM EDTA, pH 7.4) and 0.1% SDS at 658C as previously described (Johnson et al., 1988) .
Primer extension analysis
Primer extension analysis was performed as previously described , with modi®cations. Brie¯y, about 100 ng of a synthetic oligonucleotide 35-mer corresponding to the antisense strand of the murine HMG-I(Y) cDNA nucleotides 265 ± 300 (Johnson et al., 1988) was end labeled with g-32 P-ATP and T4 polynucleotide kinase (Gibco ± BRL) (Ausubel et al., 1989) . About 5610 5 c.p.m. of this labeled primer was incubated with 20 mg of total RNA isolated as described above in 50 ml of hybridization solution (60% formamide, 0.1% SDS, 20 mM Tris-HCl (pH 7.4), 400 mM NaCl, 1 mM EDTA) for 15 min at 658C and then allowed to hybridize for 20 h at 228C. The RNA and annealed primer were precipitated with ethanol, dried and suspended in 50 ml of an aqueous solution containing 0.5 mM dNTP, 50 mg of actinomycin D per ml, 1 mM vanadyl ribonucleotide complex, 50 mg of bovine serum albumin per ml, 625 U of moloney murine leukemia virus reverse transcriptase (Gibco ± BRL). The extension reaction was stopped after 1 h at 378C by addition of 5 ml of 500 mM EDTA. The solution was extracted with phenol-chloroform and the nucleic acids in the aqueous phase precipitated with ethanol, dried and then suspended in sequencing buer, denatured and run on a 6% sequencing gel (Ausubel et al., 1989) . The same oligonucleotide primer was used with the murine HMG-I(Y) cDNA to generate a sequencing ladder by the dideoxynucleotide termination method with Sequenase and [
32 P]ATP as previously described . Quantitation of autoradiograms was determined by densitometric analysis using ImageQuant TM software produced by Molecular Dynamics (Sunnyvale, CA).
RT ± PCR quantitation of HMG-I and -Y transcripts
RT ± PCR was based on the method of Chelly et al. (1988) . The method used is capable of distinguishing HMG-I and HMG-Y transcripts and an internal reference standard (IS) as diagrammed in Figure 4a . This IS was generated by modi®cation of the murine HMG-Y isoform cDNA insert in pBluescript as follows. The HindIII site was removed from the polylinker region of the vector by digestion with HindIII, extension with DNA polymerase to ®ll in the overhangs, and subsequent religation. An internal HindIII site was then created by cleavage with BclI (BclI cleaves HMG-Y uniquely at nucleotide position 490), generation of blunt ends by ®lling in with DNA polymerase, and ligation of a 10 bp HindIII linker into this site. IS cRNA for inclusion in the RT ± PCR reactions was generated by linearizing the template with BamHI and in vitro transcription of the puri®ed digestion product with T3 polymerase. cRNA was quantitated spectrophotometrically.
The sequence of the sense 5' primer (primer A) was 5'-TGCTGCCCCACACATAGAGAAGG-3', corresponding to nucleotides 176 ± 198 of the HMG-Y isoform cDNA. The sequence of the antisense 3' primer (primer B) was 5'-CTTGTCAGGATGGGGCAGGTG-3', corresponding to nucleotides 681 ± 701 of the HMG-Y isoform cDNA. These primers span the spliced region of HMG-I(Y), thus they amplify a 559 bp fragment of HMG-I, but only a 526 bp fragment of HMG-Y because it lacks the 33 nucleotide stretch that distinguishes I from Y (Figure 4a ). They generate a 540 bp fragment from the IS that can be cleaved by HindIII generating products of 322 and 218 bp; endogenous HMG-I and -Y products are resistant to HindIII cleavage.
RT ± PCR was carried out using the Promega Access system (Madison, WI) with some modi®cations of the manufacturer's protocol. Total RNA samples were ®rst treated with RNase-free DNaseI which was heat-inactivated at 758C according to the method of Huang et al. (1996) . RT and PCR reactions were carried out in the same tube using AMV reverse transcriptase and T¯DNA polymerase. Reaction mixtures contained 0.25 mg total RNA, *2610 6 molecules IS cRNA, 2 mCi of 3000 Ci/mmol [a-32 P]dCTP, 5 pmol each of primers A and B, and 0.2 mM dNTPs. Reactions were incubated in a Perkin Elmer GeneAmp PCR System 9600 at 488C for 45 min for RT, followed by 2 min at 948C to inactivate the AMV RT, then 20 cycles of denaturation at 948C for 30 s, annealing at 608C for 1 min, and extension at 728C for 1 min were carried out followed by a ®nal 7 min extension at 728C.
A 12 ml aliquot of each sample was digested with HindIII and separated by 6% PAGE. DNA size markers were loaded in an adjacent lane, and following electrophoresis, this lane was removed and stained with ethidium bromide in order to verify the size of the radioactive bands. The remainder of the gel was dried and autoradiography was performed with Kodak X-Omat AR ®lm with intensifying screens at 7708C. Radioactive bands were quantitated with either a Scanalytics AMBIS 101/SL (San Diego, CA) radioanalytic imaging detector or by scanning densitometry of the exposed ®lm.
Protein extraction and Western blot analysis
HMG-I(Y) protein isolation and Western blot analysis were performed as previously described (Disney et al., 1989) , with modi®cations. Brie¯y, approximately 2 ± 3610 7 cells were scraped from ®ve (100 mm) plastic tissue culture plates with a rubber policeman, transferred to a 1.5 ml Eppendorf tube and pelleted by centrifugation. The cell pellet was resuspended by vortexing in 200 ml of ice cold (48C) 2.5 M (i.e. 5%) perchloric acid, and then rapidly frozen in a dry ice bath. The frozen cells were rapidly thawed at 378C and insoluble materials again pelleted by centrifugation at 48C. The proteins in the acid soluble supernatant were precipitated by addition of cold (48C) trichloroacetic acid (TCA) to a ®nal concentration of 25% TCA and, after 30 min sitting on ice, pelleted by centrifugation. The pelleted proteins were washed with 1 ml of cold acetone (100%, 48C) and dried under vacuum. Equal aliquots of protein were subjected to electrophoresis on either a precast 8 cm NuPAGE 10% Bis-Tris gel from Novex (San Diego, CA) ( Figure 5 ) or a 16 cm 15% SDSpolyacrylamide gel (Figure 6 ). Western blot transfer to nitrocellulose membranes followed the procedures described by Towbin et al. (1979) , and the transferred HMG-I and -Y proteins were detected with a speci®c anti-HMG-I(Y) rabbit polyclonal antibody (Fashena et al., 1992; John et al., 1995) raised against puri®ed recombinant HMG-I protein (Nissen et al., 1991) employing an enhanced chemiluminescence detection procedure (Ausubel et al., 1989) using`SuperSignal Substrate' supplied by Pierce (Rockford, IL).
